IP Library Granted Patent US 10,022,450
Granted Patent B2
US 10,022,450 · App. 15/241,221 · Granted Jul 17, 2018

Regulation of specific spinal neurons regulating pain transmission via chimeric toxins

Inventors: Eric A. Johnson (Madison, WI); Sabine Pellett (Madison, WI); William H. Tepp (Stoughton, WI); Tony L. Yaksh (San Diego, CA); Marc Marino (San Diego, CA); Qinghao Xu (San Diego, CA)
Assignees: Wisconsin Alumni Research Foundation; The Regents of the University of California
A61K47/48238A61K9/0085A61K38/164A61K38/4893A61K47/62C07K7/22C07K14/33C07K14/57545C07K14/70C07K14/72C12N9/96C12Y304/24069C07K2319/01C07K2319/33C07K2319/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,022,450
App. No.
15/241,221
Granted
Jul 17, 2018
Kind
B2
Abstract

A chimeric toxin is disclosed comprising a peptide ligand specifically targeting neurons involved in pain processing; and a clostridial neurotoxin light chain, wherein the ligand is linked to the light chain. The methods of preparing such chimeric toxin and the method of using the chimeric toxin to regulate pain transmission are also disclosed.

Claims (11)

1. A method for inhibiting pain transmission in a patient in need thereof, the method comprising the step of

administering to said patient a formulation comprising an effective amount of a chimeric toxin of a chimeric toxin comprising

(i) a peptide ligand specifically targeting neurons involved in pain processing, wherein the ligand is Substance P (SEQ ID NO:1); and

(ii) a clostridial neurotoxin light chain,

wherein the ligand is linked to the light chain to form a chimeric toxin, and wherein the chimeric toxin does not comprise a translocation domain.

2. The method of claim 1 , wherein the formulation is delivered into lumbar intrathecal puncture space.

3. The method of claim 2 , wherein the formulation is in a water based isotonic vehicle prepared freshly prior to the administration.

4. The method of claim 1 , wherein the effective amount is in the range of 5 to 10000 U typically delivered in a volume of 1 mL.

5. The method of claim 4 , wherein the effective amount is in the range of 0.005 to 1000 micrograms of the ligand.

6. The method of claim 5 , wherein the effective amount is 0.5 micrograms.

7. The method of claim 1 , wherein the pain arises from cutaneous injury and inflammation, musculoskeletal injury and inflammation, visceral inflammation or injury, peripheral nerve injury as caused by chemicals, metabolic disease, physical injury, and mixtures thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2018
From: JOHNSON, ERIC; TEPP, WILLIAM; PELLETT, SABINE
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 046403/0181 →
CONFIRMATORY LICENSE Recorded Jul 3, 2018
From: UNIVERSITY OF WISCONSIN MADISON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046473/0677 →
Continuity (3)
Division 14181241 · Feb 14, 2014
Provisional Application 61775116 · Mar 8, 2013
Related Publication 20160361429A1 · Dec 15, 2016
Cited By (1)
US 12,642,873